Our analyses provided evidence for the presence of tumour-infiltrating CD8+ T cells, a brachyury tumour antigen-directed immune response and the rationale for ICI therapy that resulted in a clinical and radiographic response in a PDC patient treated with nivolumab. The gene discussed is CD8A; the disease is neoplasm.